
In compliance with article 118 "authorization of advertising to the public" of the legislative decree of 24 April 2006, number 219
INDICATIONS
VENORUTON is indicated in the treatment of symptoms related to venous insufficiency; states of capillary fragility.
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.
WARNINGS AND PRECAUTIONS FOR USE
Patients suffering from lower limb edema due to heart, kidney or liver disease should not take Venoruton as the effect of Venoruton is not proven in these indications. Pediatric population The use of Venoruton is not recommended in children. Venoruton gel: The use, especially if prolonged, of products to be applied to the skin can give rise to sensitization phenomena. In this case you should stop treatment and contact your doctor to institute suitable therapy. Important information about some excipients Venoruton 1000 mg powder contains: - sodium saccharin: this medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. Venoruton 500 mg film-coated tablets contain the azo coloring agent: - sunset yellow aluminum lake (E 110): may cause allergic reactions. Venoruton gel contains: - benzalkonium chloride: this medicinal product contains 0.391 mg of benzalkonium chloride per dose equivalent to 0.05 mg/g. Benzalkonium chloride may irritate the skin. If you are breastfeeding, do not apply this medicine to your breasts because your baby may ingest it with his milk.
INTERACTIONS
To date, no specific interaction of oxerutin with other medicinal products has been reported. In vitro data on a possible modulation of CYP3A activity by oxerutin components (quercetin and rutin present in trace amounts) are conflicting. Venoruton gel: no interactions with medicinal products have been reported.
SIDE EFFECTS
Venoruton oral formulations: Safety profile summary Venoruton may in rare cases cause gastrointestinal side effects or skin reactions such as gastrointestinal disorders, flatulence, diarrhoea, abdominal pain, stomach discomfort, dyspepsia, rash, itching or hives. Very rare is the appearance of dizziness, headache, hot flashes, tiredness or hypersensitivity reactions such as anaphylactoid reactions. Table of adverse reactions Side effects are listed below by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1,000); very rare (< 1/10,000), or not known (frequency cannot be estimated from the available data). Within each frequency class, undesirable effects are indicated in order of decreasing seriousness.
Classes Organ Systems / Frequency | Adverse reactions
Immune system disorders
Very rare | Adverse reactions: Anaphylactoid reactions
Very rare | Adverse reactions: Hypersensitivity reactions
Nervous system disorders
Very rare | Adverse reactions: Dizziness
Very rare | Adverse reactions: Headache
Vascular pathologies
Very rare | Adverse reactions: Hot flashes
Gastrointestinal disorders
Rare | Adverse reactions: Gastrointestinal disorders
Rare | Adverse reactions: Flatulence
Rare | Adverse reactions: Diarrhoea
Rare | Adverse reactions: Abdominal pain
Rare | Adverse reactions: Stomach problems
Rare | Adverse reactions: Dyspepsia
Pathologies of the skin and subcutaneous tissue
Rare | Adverse reactions: Rash
Rare | Adverse reactions: Itching
Rare | Adverse reactions: Urticaria
Systemic pathologies and conditions relating to the administration site
Very rare | Adverse reactions: Tiredness
Venoruton gel: Safety profile summary Venoruton gel is well tolerated. Rare cases of sensitization with the appearance of skin reactions have been observed. These symptoms disappear when treatment is stopped. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.








